Gelstat GSAC · USD

Its shares trade under the ticker GSAC. It has been listed since 23 April 1993. In the fiscal year to 31 December 2025, it reported revenue of $267,962 and a net loss of $326,575. At that date it held total assets of $269,576 and shareholders' equity of −$1.3m.

GelStat Corp. engages in the research, development, and commercialization of pharmaceutical products. The company is headquartered in Hunt Valley, Maryland. The firm is engaged in the development and marketing of over-the-counter (OTC) and other non-prescription consumer healthcare products. The firm offers various products, which include GelStat Migraine, Chews 2 Lose, All Natural Speed and GelStat Sleep. GelStat Migraine is a solution designed for the pain relief from migraine headaches. GelStat Migraine is a formulation based on the medicinal plants feverfew (tanacetum parthenium) and ginger (zingiber officinale). Feverfew and ginger contain various compounds, including sesquiterpene lactones and flavonoids. Chews 2 Lose is a diet aide in the form of an all-natural appetite suppressant gum designed to help dieters from cheating. All Natural Speed is an all natural energy product in capsule form. GelStat Sleep provides relief from sleep disorders and its associated symptoms. Matix Medica LLC (Mastix) is the Company's subsidiary.

Figures and description from our data supplier, not checked against the company's own report.

• Mr. Adrian GoldfarbNon-Executive Chairman of the Board
• Mr. Robert EsteyChief Executive Officer
• Mr. Gerald KieftChief Financial Officer, Director, since 2008$84,375
• Paul BuchaDirector

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.